Results of a pilot study investigating dual CD19 and CD22 targeted CAR T therapy for treatment of relapsed B-cell lymphomas.
Home / Resource Library / Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies